Unicon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unicon

Quick Facts

Property Description
Active ingredient Choline Theophyllinate (Oxtriphylline)
Form Tablet, capsule, syrup, elixir (for oral administration)
Pharmacological class Bronchodilator, Methylxanthine Derivative
Common use Management of reversible airway obstruction
Origin Synthetic chemical salt

The Identity and Classification of Unicon (Choline Theophyllinate)

Unicon is a medicinal product containing the active ingredient Choline Theophyllinate, which is also known by the synonym Oxtriphylline. This compound is formally classified as a bronchodilator and belongs to the broader group of methylxanthine derivatives, which is its chemical designation within the ATC classification system.

The primary function of Choline Theophyllinate is to help relax and expand the smooth muscles of the bronchial airways. This class of compounds is used for addressing airflow limitation in the lungs. This means the medicine works to reduce tightness in the chest and make breathing easier.

Composition, Forms, and Origin of the Substance

The active component, Choline Theophyllinate, is a synthetic chemical salt created by combining Theophylline, the main therapeutic agent, with the organic substance Choline. This salt structure enhances the molecule's solubility and stability for efficient oral administration, a key differentiating factor from some pure Theophylline preparations.

Unicon is consistently manufactured as a single-entity product and is available in various dosage forms, including tablets, capsules, syrup, and specialized sustained release preparations. The use of sustained release forms for methylxanthines helps to maintain steady therapeutic concentrations over time, which supports the drug's purpose of managing chronic conditions.

General Purpose: How This Drug Type Manages Airflow

the general purpose of Choline Theophyllinate is to help restore and sustain efficient airflow through the respiratory passages. By promoting smooth muscle relaxation within the bronchial airways, it directly counters the physical narrowing of the air passages.

This action contributes to overall respiratory stability, providing the general benefit of mitigating breathing difficulties and facilitating more efficient processes of inhalation and exhalation for the patient. The use of this drug type is part of a standard clinical approach to improving lung function and reducing airway responsiveness.

Regulatory References

  1. NIH MedlinePlus on Theophylline

What side effects are possible with Unicon?

Possible Side Effects and Safety Information

The safety profile of Unicon (Choline Theophyllinate) is officially documented by regulatory agencies, detailing adverse reactions by frequency and the body system affected. The most commonly reported adverse reactions involve the Gastrointestinal System (such as nausea, vomiting, abdominal pain) and the Nervous System (including headache, tremor, restlessness, and insomnia). Cardiac effects like palpitation and tachycardia are also commonly reported.


Serious Adverse Reactions and Risk Context

The regulatory labeling explicitly lists rare but clinically significant events. These serious adverse reactions include central nervous system disturbances such as convulsions and delirium, severe cardiovascular events like ventricular arrhythmias and dysrhythmia, gastrointestinal bleeding, and the hematological condition pure red cell aplasia. These critical reactions are not always preceded by milder symptoms and are often associated with elevated serum concentrations of the drug.


Population and Timing-Related Safety Notes

Adverse reactions that are less severe, such as nausea and slight restlessness, are officially documented as occurring more frequently when initiating therapy and are usually transient. Specific safety considerations are defined for certain patient groups where the risk profile is altered due to documented changes in drug clearance. These include older patients, children (due to increased sensitivity), and individuals with impaired liver function or congestive heart failure.

Official restrictions and contraindications are established, barring use in individuals with documented conditions such as active peptic ulcer disease or certain forms of coronary artery disease. The regulatory safety information strictly maintains that the use of other xanthine-containing preparations concurrently is constrained.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Unicon (Choline Theophyllinate) leads to documented manifestations of severe methylxanthine toxicity, which is consistent with the toxicology profile of its active component, Theophylline. This toxicity can occur from acute ingestion or from chronic accumulation.

Documented Manifestations and Severe Outcomes

Official regulatory information details that overdose frequently presents with pronounced gastrointestinal effects such as severe nausea and persistent vomiting. More serious manifestations involve the Central Nervous System (CNS), including severe tremors, agitation, and the life-threatening event of seizures, which carries a risk of permanent damage. Cardiovascular effects are also critical, manifesting as various arrhythmias (e.g., ventricular tachycardia) and tachycardia. Metabolic changes often include hypokalemia (low potassium) and hyperglycemia.

Mandated Emergency Actions

The most severe symptoms—especially the onset of seizures, fainting, or a rapid/irregular heartbeat—are explicit triggers for patients to seek emergency medical attention immediately, as prescribed in regulatory guidance. Management is primarily symptomatic and supportive, since no specific antidote is known. Procedures such as activated charcoal administration and continuous serum theophylline concentration monitoring are often required in a hospital setting. Regulatory documents note that patients with conditions like hepatic impairment or the elderly may be at increased risk of toxicity.

Therapeutic Uses of Unicon

What Unicon Treats: Main Uses and Benefits

Unicon (Choline Theophyllinate) is commonly used for managing symptoms associated with various chronic obstructive lung diseases. As a systemic support medication, its primary therapeutic purpose is to provide supportive relief from symptoms related to constricted breathing. The compound is used for easing symptoms such as wheezing, shortness of breath, and chest tightness caused by conditions like asthma, chronic bronchitis, and emphysema.

The medication is relevant for easing symptoms in conditions characterized by persistent or recurrent airflow limitation, commonly used across therapeutic domains involving Bronchial Asthma and COPD. Its core benefit is addressing symptom clusters that interfere with daily comfort. This is particularly relevant in scenarios where sustained support is needed to help manage episodic manifestations of the disease, such as exercise-induced bronchospasm.

“It provides supportive relief that helps patients cope more steadily with symptom fluctuations.”


Quick Facts: Therapeutic Support

Primary Focus Managing persistent and recurrent symptoms.
Use Context Applied in conditions characterized by chronic symptom patterns.
Key Benefit Supports the patient by easing the overall symptom load.

Regulatory References

  1. Theophylline: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Absolute Contraindications (Who Must Not Use Unicon)

Official regulatory labeling dictates that Unicon (Choline Theophyllinate) is contraindicated and must not be used in specific patient groups. These include individuals with a history of hypersensitivity to the medicine, Theophylline, or any other xanthine derivatives. The drug is also strictly prohibited for patients with an active peptic ulcer and in cases of coronary artery disease where myocardial stimulation could be judged harmful.


Restricted and Conditional Use

Caution is required in populations with documented reduced drug clearance, as this increases the risk of toxicity. This includes patients with impaired liver function (such as cirrhosis), those with Congestive Heart Failure, and older adults (typically gt 55 years), who may be more sensitive to the drug's effects. Clearance may also be reduced in patients with sustained high fever.

Age Group Regulatory Status
Children lt 1 year Use requires caution; more likely to have serious effects
Adults & Children ge 1 year Use is generally established
Older Adults Requires caution due to reduced clearance and increased sensitivity

Pregnancy and Lactation Eligibility

The active ingredient is historically assigned to FDA Pregnancy Category C, meaning its use is conditional and recommended only when the benefit outweighs the potential risk. The drug is excreted into human milk, and due to the potential for adverse effects in nursing infants, regulatory bodies recommend a decision be made to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions involving Unicon (Choline Theophyllinate) are primarily governed by the drug's metabolism and are officially documented in regulatory labeling.

Classification Interacting Agents (Examples) Official Regulatory Statement
Formal Restrictions Other Xanthine Derivatives (e.g., Aminophylline), Ciprofloxacin Co-administration with other xanthine derivatives is formally restricted due to risk of systemic overload. Combination with Ciprofloxacin is associated with serious and fatal reactions.
Increased Exposure Cimetidine, Erythromycin, Fluvoxamine, Allopurinol (high dose) These agents decrease Theophylline clearance by inhibiting Cytochrome P450 enzymes (e.g., CYP1A2), leading to increased plasma concentrations.
Decreased Exposure Phenytoin, Carbamazepine, Rifampin, Tobacco Smoking, St. John's Wort These substances induce hepatic enzymes, which causes an acceleration of Theophylline metabolism and a reduction in its serum concentration.
Pharmacodynamic Effects Halothane, Sympathomimetic Amines, Adenosine Increases the documented risk of specific adverse effects, such as ventricular arrhythmias with Halothane, or antagonizes the therapeutic efficacy of Adenosine.

Population-Specific and Dietary Notes: Official documents note that conditions like Congestive Heart Failure or Liver Disease reduce Theophylline clearance, which amplifies the risk of interactions. Additionally, consumption of excessive caffeine may contribute to side effects, and enteral feedings can interfere with absorption, requiring time separation.

Mechanism of Action

The mechanism of Unicon is driven by its active component, Theophylline, which concurrently modulates multiple biological pathways critical to respiratory function, operating through both rapid cellular signaling and slower genomic control.

Modulation of Airway Smooth Muscle Tone

This domain covers the drug's action as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes, leading to increased levels of the intracellular messenger cAMP within bronchial smooth muscle cells. The resulting molecular cascade causes a reduction in muscle tension, resulting in relaxation of the bronchial smooth muscle tissue.

️ Interaction with Receptors and Immune Signaling

The drug functions as a non-selective antagonist of adenosine receptors in the airways and immune cells, which blocks the effects of a signaling molecule that promotes restriction and mediator release. This interaction modulates localized immune responses by limiting the output of spasmogenic mediators, influencing the biological reactivity of the airways.

Genomic Regulation of Inflammation

Operating on a slower timeline, Unicon's active component supports the restoration of function of the nuclear enzyme Histone deacetylase 2 (HDAC2). This genomic action suppresses pro-inflammatory gene transcription, resulting in a reduction in inflammatory cell product synthesis at the cellular level.

Optional — contextual note (1 sentence): These distinct mechanisms, which also enhance the contractility of the respiratory muscles, activate at different drug concentrations and determine the breadth of the drug’s action.

Dosage and Administration Information

How Unicon is Used

Unicon (Choline Theophyllinate) is primarily intended for oral administration, utilizing forms such as tablets, capsules, and liquids. The active component, Theophylline, is also used for intravenous (IV) use in acute settings, typically in a hospital under medical supervision.


Standard Dosage and Frequency

Oral dosing is individualized and adjusted based on the patient’s clinical status and therapeutic drug monitoring. The following serves as a high-level overview of standard regimens for chronic use:

Regimen Feature Standard Instruction
Initial Adult Dose 300 to 400 mg daily.
Maintenance Dose Adjusted based on serum levels, up to 600 mg per day (for healthy, non-smoking adults).
Frequency Extended-release forms are taken once or twice daily (e.g., every 12 hours).

Dosage adjustments (titration) are made at intervals of no less than three days to allow the drug concentration to stabilize, a core part of the use protocol.


Administration Requirements

Standard practices are observed to ensure proper administration and sustained release:

  • Extended-Release Forms: Tablets and capsules formulated for extended release must be swallowed whole. They must not be crushed, chewed, or broken to preserve their release mechanism.
  • Measuring Liquid: When using the oral solution or elixir, a calibrated measuring device is required for accurate dosing.
  • Population Specifics: Doses for older adults (over 60) and patients with hepatic impairment (liver disease) are often lower, with the maximum dose for the elderly often not exceeding 400 mg per day.

Recent Clinical Evidence

Research evidence / Overview of studies for Unicon

Evidence for Use in Chronic Asthma

Research has explored the agent's research applications in conditions characterized by fluctuating or episodic manifestations of chronic asthma. The primary evidence base comes from short-term and intermediate-term Randomized Controlled Trials (RCTs), supported by subsequent Systematic Reviews. Researchers were particularly focused on outcomes related to physical discomfort and functional imbalance within the airways. Studies monitored changes in lung function between subject groups (e.g., those receiving the agent versus those receiving placebo) during the trial period. These patterns were observed, particularly in trials lasting up to several months. However, the evidence quality varies across studies due to heterogeneity in patient groups and dosing strategies. Long-term effects are not fully established, and research provides context regarding short-term changes.


Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Unicon was studied for its research applications in conditions marked by functional limitations and systemic imbalance, such as chronic obstructive pulmonary disease (COPD). The outcomes monitored focused on physiological strain, including changes in FEV1 and levels of oxygen and carbon dioxide in the blood. Studies tracked outcomes related to daily functioning, such as changes in exercise capacity, which were observed in some reports. However, the findings were mixed across different trials and the results apply only to the populations studied. There is limited information for long-term outcomes on factors like survival, and comparative evidence is lacking against current standard therapies.


Evidence for Preventing Exercise-Induced Bronchospasm (EIB)

Research has explored the agent's research applications in conditions associated with acute or disruptive episodes, specifically exercise-induced bronchospasm (EIB). The research primarily consists of Controlled Clinical Trials, comparing a single dose to a placebo before a standardized exercise challenge. Findings describe patterns observed in these acute studies, indicating the duration for which the agent was observed in relation to the specific drop in lung function. However, the research does not provide insight into any potential long-term changes to the condition itself, and subgroup findings are uncertain due to the typically modest sample sizes.


Long-Term Studies and Durability of Effect

Studies were conducted for periods ranging from several weeks up to one year to explore short-term symptom changes and maintenance patterns. However, data are still emerging, and long-term effects are not fully established. The available evidence primarily provides insight into symptom patterns during these defined study periods.


Gaps and Uncertainties in the Research Evidence

While Unicon was studied for its research applications, certainty remains low in several areas. Key limitations include that many of the core studies are older, leading to evidence heterogeneity in methods. The comparative evidence is lacking against newer classes of maintenance treatments. The evidence landscape indicates areas of established research and areas of uncertainty; specifically, findings were mixed regarding some patient-reported outcomes, and there is limited information for long-term outcomes related to disease modification or all-cause mortality. Research is ongoing, but the long-term effects on chronic disease progression are not fully established.

Key Studies & References

  1. Theophylline: MedlinePlus Drug Information (General Overview/Indications)
  2. Label: THEOPHYLLINE tablet, extended release - DailyMed (Regulatory/Indications)
  3. Theophylline - StatPearls - NCBI Bookshelf (COPD/Asthma Management, General Research)
  4. Chronic Use of Theophylline and Mortality in Chronic Obstructive Pulmonary Disease: A Meta-analysis (Long-term Outcomes/COPD)
  5. Effectiveness of terbutaline and theophylline alone and in combination in exercise-induced bronchospasm (EIB RCT)

Frequently Asked Questions (FAQ)

Common questions about Unicon (FAQ)


Q: Is Unicon a steroid?

A: No, Unicon is not a steroid. According to regulatory documents, the medicine is classified as a methylxanthine derivative and a bronchodilator, a different class of medicine from corticosteroids (steroids), which work through separate biological pathways.

Q: How long does the effect of Unicon typically last after one use?

A: The duration of effect relates to the elimination half-life of its active ingredient, Theophylline. Official pharmacokinetic data indicates the average half-life is approximately 8 hours in healthy, non-smoking adults. However, this is an average, and the exact time it remains active in the body can vary significantly based on individual factors like age, smoking status, and other health conditions.

Q: Do I need a prescription to get Unicon?

A: Yes. Unicon (Choline Theophyllinate) is typically classified as a prescription medicine for its indicated uses. This classification is consistent across major health authorities, meaning it requires a licensed healthcare professional’s authorization.

Q: Is it normal to feel a little dizzy after taking Unicon?

A: Official adverse reaction reports indicate that feeling dizzy or lightheaded is a reported side effect of the active ingredient. These effects are classified as central nervous system (CNS) disturbances. If unexpected or severe symptoms occur, consult with a healthcare professional.

Q: What types of food or drinks should be avoided while using Unicon?

A: Official warnings advise caution regarding substances like excessive caffeine, as it may contribute to side effects. The warnings generally note caution against combining the drug with alcohol. Additionally, certain regulatory notes reference that enteral feedings can interfere with absorption.

Q: Can Unicon interact with my blood pressure medication?

A: Regulatory information indicates the active ingredient can interact with certain types of heart and blood pressure medications. For example, it may interact with drugs that affect the heart rate, such as sympathomimetic amines. Official documents note that it is used with caution in patients with known hypertension (high blood pressure).

Q: Are there any known interactions between Unicon and herbal supplements?

A: Yes, specific herbal supplements are noted in the official prescribing information. The product label specifically lists that the herbal supplement St. John's Wort can accelerate the metabolism of Unicon’s active ingredient. This action can potentially reduce the drug concentration in the body.

Q: Has Unicon been studied in children or adolescents?

A: Official regulatory documents indicate that the active ingredient has established use in children aged 1 year and older. However, official safety notes highlight that children under 1 year of age may have increased sensitivity and a higher risk of serious effects, a situation where caution is advised.

Q: What happens if I forget to take my Unicon dose?

A: Patient counseling information generally states that a missed dose is handled by taking the next dose at the scheduled time. Regulatory information advises against doubling the dose to make up for the one that was missed.

Q: Is Unicon considered a controlled substance?

A: No. Official government listings, such as those maintained by the U.S. Controlled Substances Act, do not classify Unicon (Choline Theophyllinate) as a controlled substance.

Q: What should I do if a potential side effect feels severe?

A: Official safety information documents that serious adverse reactions, such as seizures or severe arrhythmias (irregular heart rhythms), are possible. If signs of a severe or life-threatening reaction occur, official guidance is to contact emergency medical services or a healthcare professional immediately.

Q: Does Unicon affect blood sugar levels?

A: The side effect profiles for the active ingredient indicate that it has the potential to cause hyperglycemia, which is an elevated blood sugar level. Official documentation reports this as a possible adverse reaction.

Q: Can I drive or operate machinery while taking Unicon?

A: Since Unicon is known to cause central nervous system effects such as dizziness, tremor, and headache, official patient counseling advises caution. The labeling suggests that the ability to perform tasks requiring full alertness may be affected due to these reported side effects.

Q: Why do official documents warn against using Unicon with alcohol?

A: Official warnings caution against combining alcohol and Unicon’s active ingredient. This general caution is given to limit the potential for increased side effects and reduce the overall risk for adverse reactions.

Q: Are there any specific laboratory tests required when using Unicon?

A: Yes, due to the drug's narrow therapeutic range (the difference between a helpful level and a harmful level), it requires frequent therapeutic drug monitoring. This means the specific concentration of the medicine in the blood (serum theophylline concentration) is monitored regularly to adjust the dose.

Q: Do I need to take Unicon at a specific time of day?

A: Official product information describes administration timing for extended-release forms, such as taking them after meals to minimize stomach upset and support consistent absorption. This usually involves separating doses by approximately 12 hours.

Q: What is the official black box warning for Unicon, if any?

A: Yes, the active ingredient is associated with a Black Box Warning (a prominent safety warning). This warning highlights the potential for serious and life-threatening side effects, such as cardiac arrhythmias and seizures, that may occur if the drug reaches toxic blood levels.

Q: Does Unicon cause mood changes or depression?

A: The official side effect profile lists several central nervous system effects, including restlessness, agitation, and irritability. However, the product's primary adverse reaction list does not consistently include depression as a commonly reported adverse event.

Q: Is Unicon known to affect fertility?

A: Studies conducted on the active ingredient in animals have not indicated that the medication causes impairment of fertility. Official regulatory documents provide this data as part of the nonclinical toxicology profile.

Q: What does the term 'contraindication' mean regarding Unicon?

A: A contraindication is a strict regulatory term used in official documentation. It means that the medication must not be used in specific patient situations—such as having an active peptic ulcer or a history of hypersensitivity—because the risk of harm clearly outweighs any potential therapeutic benefit.

Q: What is the half-life of Unicon?

A: The elimination half-life, which is the time it takes for half of the drug to be eliminated from the bloodstream, is typically reported to be about 8 hours for non-smoking adults. Official prescribing information indicates that factors like age, smoking status, and liver function can cause this half-life to vary significantly.

Q: Are there different strengths or forms of Unicon available?

A: Yes. The active ingredient is available in various forms, including extended-release tablets, capsules, and oral liquids. It is also manufactured in multiple specific strengths, which allows for individualized dosing based on monitoring results.

Q: Does Unicon require special monitoring for kidney function?

A: The active ingredient is primarily eliminated by the liver, but the drug is partially excreted by the kidneys. Official guidance advises caution in patients with impaired renal (kidney) function. The need for dosage adjustment and monitoring is considered in these cases.

Q: How is Unicon eliminated from the body?

A: The active ingredient, Theophylline, is primarily eliminated through a two-step process. The majority (about 90%) is eliminated through metabolism (breakdown) in the liver. The remaining portion and its metabolites are then excreted via the kidneys.

How should Unicon be stored and disposed of?

Storage and Disposal of UNICON Tablets (Choline Theophyllinate)

Unicon tablets must be stored according to official regulatory specifications to maintain the product's 3-year stability.

Mandatory Storage Conditions

Requirement Official Instruction
Temperature Do not store above 30°C; store in a cool, dry place.
Protection Keep in the original, tightly closed package; protect from direct light and moisture.
Safety Keep all medicines out of the sight and reach of children.

Disposal Requirements

When discarding unused or expired Unicon, follow formal protocols. The preferred method is to utilize an official drug take-back program. If this is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (such as dirt or used coffee grounds), and sealed in a container before disposal in household trash. Avoid discharge into drains or water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unicon found in:

A-Z Index: